Previous 10 | Next 10 |
2023-12-18 23:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-18 20:57:13 ET Summary Merus N.V. is a biotech company developing novel bispecific antibodies, with two drugs in development for unmet needs in head and neck cancer and solid tumors. Petosemtamab, targeting EGFR and LGR5, showed promising results in a phase 1/2 trial for h...
2023-12-04 11:44:29 ET More on Merus Seeking Alpha’s Quant Rating on Merus Historical earnings data for Merus Financial information for Merus For further details see: Merus falls after updated data for lung cancer therapy
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antib...
2023-11-30 12:17:22 ET More on AbbVie, ImmunoGen, etc. AbbVie: Get Ready For More Painful Downside AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade) Buy The Dip In AbbVie? Nope, Not This Time Biggest stock movers today: Sna...
- Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m. SGT - Poster presentation on MCLA-129 in previously treated HNSCC on Saturday, December 2 at 17:50 p.m. SGT -&...
2023-11-02 17:56:28 ET More on Merus Merus: Petosemtamab And Zeno The Driving Forces Behind Investment Returns Merus prices stock offering to raise $150M Merus plans for stock offering, size not disclosed Seeking Alpha’s Quant Rating on Merus H...
– Petosemtamab in combination with Keytruda 1L initial interim clinical data planned for 1H24; 2L+ HNSCC monotherapy clinical update planned 2024 – Zeno interim clinical data continue to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Merus N.V. (MRUS) is expected to report $-0.73 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...